Trial Profile
Phase I, dose-escalation study evaluating the safety and tolerability of LY-2510924 in patients with Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Nov 2015
Price :
$35
*
At a glance
- Drugs LY 2510924 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 27 Nov 2015 New trial record